These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 8387881)

  • 1. Prolonged, alternating chemotherapy for extensive small cell lung cancer. A Southwest oncology Group study.
    Livingston RB; Crowley JJ; Thompson T; Williamson SK; Meyers FJ; O'Rourke T; Neefe JR
    Cancer; 1993 Jun; 71(11):3509-13. PubMed ID: 8387881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: a phase II study of the Southwest Oncology Group (SWOG-9229).
    Thomas CR; Giroux DJ; Stelzer KJ; Craig JB; Laufman LR; Taylor SA; Goodwin JW; Crowley JJ; Livingston RB
    Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1039-47. PubMed ID: 9539558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
    Furuse K; Fukuoka M; Nishiwaki Y; Kurita Y; Watanabe K; Noda K; Ariyoshi Y; Tamura T; Saijo N
    J Clin Oncol; 1998 Jun; 16(6):2126-32. PubMed ID: 9626212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
    Wolf M; Havemann K; Holle R; Gropp C; Drings P; Hans K; Schroeder M; Heim M; Dommes M; Mende S
    J Clin Oncol; 1987 Dec; 5(12):1880-9. PubMed ID: 2824710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
    Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
    J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
    Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
    Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer.
    Fukuoka M; Furuse K; Saijo N; Nishiwaki Y; Ikegami H; Tamura T; Shimoyama M; Suemasu K
    J Natl Cancer Inst; 1991 Jun; 83(12):855-61. PubMed ID: 1648142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience of a German multicenter study group with ifosfamide in small cell lung cancer.
    Havemann K; Wolf M; Drings P; Hans K; Schroeder M; Holle R; Flechtner H; Goerg R; Becker H
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):9-18. PubMed ID: 2539648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: randomized trial, can it improve survival of patients with good prognostic factors?
    Masutani M; Ochi Y; Kadota A; Akusawa H; Kisohara A; Takahashi N; Koya Y; Horie T
    Oncol Rep; 2000; 7(2):305-10. PubMed ID: 10671676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer.
    Ohnoshi T; Hiraki S; Ueoka H; Kiura K; Kamei H; Horiguchi T; Kodani T; Maeda T; Tabata M; Shibayama T
    Cancer; 1993 Sep; 72(5):1597-601. PubMed ID: 8394202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.
    Hong WK; Nicaise C; Lawson R; Maroun JA; Comis R; Speer J; Luedke D; Hurtubise M; Lanzotti V; Goodlow J
    J Clin Oncol; 1989 Apr; 7(4):450-6. PubMed ID: 2538577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.
    Murray N; Livingston RB; Shepherd FA; James K; Zee B; Langleben A; Kraut M; Bearden J; Goodwin JW; Grafton C; Turrisi A; Walde D; Croft H; Osoba D; Ottaway J; Gandara D
    J Clin Oncol; 1999 Aug; 17(8):2300-8. PubMed ID: 10561291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternating chemotherapy with cyclophosphamide, doxorubicin, vincristine and cisplatin, etoposide followed by prophylactic cranial and thoracic irradiation for small cell lung cancer (SCLC): long-term results.
    Ardizzoni A; Fusco V; Pennucci C; Baldini E; Orsatti M; Vitale V; Bonavia M; Baracco F; Mereu C; Rosso R
    Anticancer Res; 1991; 11(2):681-4. PubMed ID: 1648333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination chemotherapy in small cell lung carcinoma. A randomized study of two intensive regimens.
    Lowenbraun S; Birch R; Buchanan R; Krauss S; Durant J; Perez C; Mill W; Vollmer R; Ogden L
    Cancer; 1984 Dec; 54(11):2344-50. PubMed ID: 6093979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial.
    Souhami RL; Rudd R; Ruiz de Elvira MC; James L; Gower N; Harper PG; Tobias JS; Partridge MR; Davison AG; Trask C
    J Clin Oncol; 1994 Sep; 12(9):1806-13. PubMed ID: 8083704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma: results of long term follow-up.
    Ueoka H; Kiura K; Tabata M; Kamei H; Gemba K; Sakae K; Hiraki Y; Hiraki S; Segawa Y; Harada M
    Cancer; 1998 Jul; 83(2):283-90. PubMed ID: 9669811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapy.
    Tummarello D; Graziano F; Mari D; Cetto G; Pasini F; Antonio S; Isidori P; Gasparini S
    Anticancer Res; 1994; 14(5B):2221-7. PubMed ID: 7840527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group.
    Ettinger DS; Finkelstein DM; Abeloff MD; Ruckdeschel JC; Aisner SC; Eggleston JC
    J Clin Oncol; 1990 Feb; 8(2):230-40. PubMed ID: 2153765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer.
    Murray N; Shah A; Osoba D; Page R; Karsai H; Grafton C; Goddard K; Fairey R; Voss N
    J Clin Oncol; 1991 Sep; 9(9):1632-8. PubMed ID: 1651995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin and etoposide alternating ifosfamide, vincristine, epirubicin in small cell lung cancer.
    Unsal M; Erturk D
    Saudi Med J; 2003 Jun; 24(6):628-31. PubMed ID: 12847592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.